source
- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalAn arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…BioPharma Dive · 22d ago↗ source
- Oberland pours up to $400M into MeiraGTx eye gene therapiesThe funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.BioPharma Dive · 23d ago↗ source
- Kailera says obesity pill succeeds in late-stage trial in ChinaThe drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.